相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibitors and chemical probes for molecular chaperone networks
Jason E. Gestwicki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Granzyme B Functionalized Nanoparticles Targeting Membrane Hsp70-Positive Tumors for Multimodal Cancer Theranostics
Maxim Shevtsov et al.
SMALL (2019)
Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in apatient with NSCLC stage IIIb inducing long-term tumor control: acase study
Konrad Kokowski et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2019)
Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress
Toshiki Kijima et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922
Annett Kuehnel et al.
CELLS (2019)
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Manni Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer
Maxim Shevtsov et al.
FRONTIERS IN IMMUNOLOGY (2019)
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer
Evan Y. Yu et al.
INVESTIGATIONAL NEW DRUGS (2018)
Regulation of heat shock transcription factors and their roles in physiology and disease
Rocio Gomez-Pastor et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Membrane heat shock protein 70: a theranostic target for cancer therapy
Maxim Shevtsov et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2018)
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
Jonathan E. Rosenberg et al.
BRITISH JOURNAL OF CANCER (2018)
EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790 M resistant mutation in lung cancer cells
Xiang Cao et al.
CANCER LETTERS (2018)
Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment
M. Garofalo et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Cellular Handling of Protein Aggregates by Disaggregation Machines
Axel Mogk et al.
MOLECULAR CELL (2018)
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas
Robert Meehan et al.
ONCOLOGIST (2018)
Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
Amanda Tomie Ouchida et al.
CELL DEATH & DISEASE (2018)
Sensitizing tumor cells to conventional drugs: HSP70 chaperone inhibitors, their selection and application in cancer models
Vladimir F. Lazarev et al.
CELL DEATH & DISEASE (2018)
Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells
Alina D. Nikotina et al.
Oncotarget (2018)
Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
Julia A. Yaglom et al.
SCIENTIFIC REPORTS (2018)
Chemotherapy with si-RNA and Anti-cancer Drugs
Kamaljeet Kaur et al.
CURRENT DRUG DELIVERY (2018)
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
Yeo Wool Kang et al.
CANCER LETTERS (2018)
Co-Delivery of Triptolide and Curcumin for Ovarian Cancer Targeting Therapy via mPEG-DPPE/CaP Nanoparticle
Lei Liu et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2018)
Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells
Sara Sannino et al.
JOURNAL OF CELL SCIENCE (2018)
Dual targeting of HSP70 does not induce the heat shock response and synergistically reduces cell viability in muscle invasive bladder cancer
Thomas Prince et al.
Oncotarget (2018)
Increased expression of heat shock factor 1 (HSF1) is associated with poor survival in gastric cancer patients
Weigang Dai et al.
DIAGNOSTIC PATHOLOGY (2018)
Small Molecule Inhibitors of HSF1-Activated Pathways as Potential Next-Generation Anticancer Therapeutics
Chiranjeev Sharma et al.
MOLECULES (2018)
Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data
Maxim Sorokin et al.
CANCERS (2018)
Adapting to stress - chaperome networks in cancer
Suhasini Joshi et al.
NATURE REVIEWS CANCER (2018)
Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic-Induced Apoptosis
Patrick Antonietti et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Peptide fragments of Hsp70 modulate its chaperone activity and sensitize tumor cells to anti-cancer drugs
Dmitry V. Sverchinsky et al.
FEBS LETTERS (2017)
HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Karem A. Court et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway
Ke Chen et al.
MOLECULAR ONCOLOGY (2017)
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
Andrew H. Ko et al.
ONCOLOGIST (2017)
The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells
Susanne Schaefer et al.
PLOS ONE (2017)
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Rina M. Mbofung et al.
NATURE COMMUNICATIONS (2017)
Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth
Richard L. Carpenter et al.
ONCOTARGET (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles
Xiangyi Li et al.
ARTIFICIAL INTELLIGENCE IN MEDICINE (2017)
KRIBB11 accelerates Mcl-1 degradation through an HSF1-independent, Mule-dependent pathway in A549 non-small cell lung cancer cells
Min-Jung Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Toxicity of triptolide and the molecular mechanisms involved
Chen Xi et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition
Daniela Schilling et al.
CANCER LETTERS (2017)
Functional inhibition of Hsp70 by Pifithrin-μ switches Gambogic acid induced caspase dependent cell death to caspase independent cell death in human bladder cancer cells
Mohammad Ishaq et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors
Anna Budina-Kolomets et al.
CANCER RESEARCH (2016)
Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70)
Xiaokai Li et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70
Matthew D. Cheeseman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas
Jessie Peh et al.
MOLECULAR CANCER THERAPEUTICS (2016)
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Jennifer O'Neil et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Novel Improved Synthesis of HSP70 Inhibitor, Pifithrin-. In Vitro Synergy Quantification of Pifithrin- Combined with Pt Drugs in Prostate and Colorectal Cancer Cells
Aoife M. McKeon et al.
MOLECULES (2016)
5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor
Shanshan Liu et al.
PROTEIN SCIENCE (2016)
Heat Shock Proteins Promote Cancer: It's a Protection Racket
Stuart K. Calderwood et al.
TRENDS IN BIOCHEMICAL SCIENCES (2016)
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy
Dieter Lemke et al.
ONCOTARGET (2016)
A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer
Linda Kinzel et al.
ONCOTARGET (2016)
Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer
Jing Xiong et al.
ONCOTARGET (2016)
Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of Cancer
Maxim Shevtsov et al.
FRONTIERS IN IMMUNOLOGY (2016)
ERK-dependent phosphorylation of HSF1 mediates chemotherapeutic resistance to benzimidazole carbamates in colorectal cancer cells
Christina T. K. Wales et al.
ANTI-CANCER DRUGS (2015)
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors
Johanna C. Bendell et al.
CANCER INVESTIGATION (2015)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
Design and synthesis of piperidine derivatives as novel human heat shock protein 70 inhibitors for the treatment of drug-resistant tumors
Yanqun Zeng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study
Katrina S. Pedersen et al.
INVESTIGATIONAL NEW DRUGS (2015)
Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
Sophie Bustany et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Validation of the Hsp70-Bag3 Protein-Protein Interaction as a Potential Therapeutic Target in Cancer
Xiaokai Li et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
Adam A. Friedman et al.
PLOS ONE (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Cancer stem cells display extremely large evolvability: alternating plastic and rigid networks as a potential Mechanism Network models, novel therapeutic target strategies, and the contributions of hypoxia, inflammation and cellular senescence
Peter Csermely et al.
SEMINARS IN CANCER BIOLOGY (2015)
Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy
David A. Proia et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial
Hanno M. Specht et al.
FRONTIERS IN IMMUNOLOGY (2015)
Suppression of the HSF1-mediated proteotoxic stress response by the metabolic stress sensor AMPK
Siyuan Dai et al.
EMBO JOURNAL (2015)
Multi-layered molecular mechanisms of polypeptide holding, unfolding and disaggregation by HSP70/HSP110 chaperones
Andrija Finka et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2015)
Affinity Purification Probes of Potential Use To Investigate the Endogenous Hsp70 Interactome in Cancer
Anna Rodina et al.
ACS CHEMICAL BIOLOGY (2014)
Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin
Wantong Song et al.
BIOMATERIALS (2014)
Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition
Anna Budina-Kolomets et al.
CANCER BIOLOGY & THERAPY (2014)
Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer
Francois Lamoureux et al.
EUROPEAN UROLOGY (2014)
VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines
Wei Wen et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2014)
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
Suqin He et al.
INVESTIGATIONAL NEW DRUGS (2014)
Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Jaime Acquaviva et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The HSP70 Modulator MAL3-101 Inhibits Merkel Cell Carcinoma
Christian Adam et al.
PLOS ONE (2014)
HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy
Ganji Purnachandra Nagaraju et al.
ONCOTARGET (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Minnelide reduces tumor burden in preclinical models of osteosarcoma
Sulagna Banerjee et al.
CANCER LETTERS (2013)
Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer
Masaki Shiota et al.
CANCER RESEARCH (2013)
Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions
David S. Hong et al.
CANCER TREATMENT REVIEWS (2013)
Isolation of a Novel Thioflavin S-Derived Compound That Inhibits BAG-1-Mediated Protein Interactions and Targets BRAF Inhibitor-Resistant Cell Lines
Marion Enthammer et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells
Wei Qi et al.
PLOS ONE (2013)
Pifithrin-μ, an Inhibitor of Heat-Shock Protein 70, Can Increase the Antitumor Effects of Hyperthermia Against Human Prostate Cancer Cells
Kazumasa Sekihara et al.
PLOS ONE (2013)
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer
Elaina M. Gartner et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers
Marc L. Mendillo et al.
CELL (2012)
Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
L. Whitesell et al.
CURRENT MOLECULAR MEDICINE (2012)
Small heat shock proteins in cancer therapy and prognosis
Amina Zoubeidi et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
Simon Pacey et al.
INVESTIGATIONAL NEW DRUGS (2012)
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Andrea Cavazzoni et al.
MOLECULAR CANCER (2012)
Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer
Masafumi Kumano et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Regulation of HSF1 Function in the Heat Stress Response: Implications in Aging and Disease
Julius Anckar et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 80 (2011)
Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
Steffen Wedel et al.
BMC CANCER (2011)
Chemical Screens against a Reconstituted Multiprotein Complex: Myricetin Blocks DnaJ Regulation of DnaK through an Allosteric Mechanism
Lyra Chang et al.
CHEMISTRY & BIOLOGY (2011)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi et al.
CLINICAL CANCER RESEARCH (2011)
KRIBB11 Inhibits HSP70 Synthesis through Inhibition of Heat Shock Factor 1 Function by Impairing the Recruitment of Positive Transcription Elongation Factor b to the hsp70 Promoter
Young Ju Yoon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
XPB, a subunit of TFIIH, is a target of the natural product triptolide
Denis V. Titov et al.
NATURE CHEMICAL BIOLOGY (2011)
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
RNA polymerase - An important molecular target of triptolide in cancer cells
Jingxuan Pan
CANCER LETTERS (2010)
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin
Ulka N. Vaishampayan et al.
CLINICAL CANCER RESEARCH (2010)
Heat shock factors: integrators of cell stress, development and lifespan
Malin Akerfelt et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
(-)-Epigallocatechin-3-gallate Is a Novel Hsp90 Inhibitor
Zhengyu Yin et al.
BIOCHEMISTRY (2009)
Heat Shock Protein 90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin Enhances EphA2+ Tumor Cell Recognition by Specific CD8+ T Cells
Mayumi Kawabe et al.
CANCER RESEARCH (2009)
Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3
Martin Gamerdinger et al.
EMBO JOURNAL (2009)
Mechanisms of drug combinations: interaction and network perspectives
Jia Jia et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo
Mara B. Antonoff et al.
SURGERY (2009)
The BAG proteins: a ubiquitous family of chaperone regulators
M. Kabbage et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Elisabeth I. Heath et al.
CLINICAL CANCER RESEARCH (2008)
Targeting Hsp90: small-molecule inhibitors and their clinical development
Tony Taldone et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70
Phoebe A. Phillips et al.
CANCER RESEARCH (2007)
Inhibition of Hsp90: A multitarget approach to radiosensitization
Kevin Camphausen et al.
CLINICAL CANCER RESEARCH (2007)
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma
Ellen A. Ronnen et al.
INVESTIGATIONAL NEW DRUGS (2006)
Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery
Joseph A. Burlison et al.
ORGANIC LETTERS (2006)
The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease
Justin Lamb et al.
SCIENCE (2006)
Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells
Chi-Keung Wan et al.
CANCER LETTERS (2006)
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90
Jie Ge et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers
Tatjana Mijatovic et al.
NEOPLASIA (2006)
Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death
SD Westerheide et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia
JE Castro et al.
BLOOD (2005)
Inhibition of Hsp90: a new strategy for inhibiting protein kinases
AS Sreedhar et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
Downstream caspases are novel targets for the antiapoptotic activity of the molecular chaperone Hsp70
EY Komarova et al.
CELL STRESS & CHAPERONES (2004)
Targeting multiple signal transduction pathways through inhibition of Hsp90
H Zhang et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2004)
Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells:: a clinical phase I trial
SW Krause et al.
CLINICAL CANCER RESEARCH (2004)
Hsp90: the vulnerable chaperone
G Chiosis et al.
DRUG DISCOVERY TODAY (2004)
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
A Kamal et al.
NATURE (2003)
Heat-shock protein 90, a chaperone for folding and regulation
D Picard
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling - Implications for studies of hsp90 and endothelial cell nitric-oxide synthase
S Dikalov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
A Maloney et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2002)
Hsp90 inhibitors as novel cancer chemotherapeutic agents
L Neckers
TRENDS IN MOLECULAR MEDICINE (2002)
Hsp90: Chaperoning signal transduction
K Richter et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2001)
The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone
MG Marcu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
